丹参酮IIA治疗大骨节病的潜在机制探讨
Exploration of the Potential Mechanisms of Tanshinone IIA in the Treatment of Kashin-Beck Disease
DOI: 10.12677/jcpm.2024.34215, PDF,    科研立项经费支持
作者: 邢 颖, 丁晓清, 阮 涛, 赵云舟, 徐 柯：黑龙江中医药大学研究生院，黑龙江 哈尔滨；张 杰*：黑龙江中医药大学附属第二医院骨伤二科，黑龙江 哈尔滨
关键词: 大骨节病；丹参酮IIA；痹症；探讨；Kashin-Beck Disease； Tanshinone IIA； Bi Syndrome； Exploration
摘要: 大骨节病(Kashin-Beck disease, KBD)是一种以关节软骨病变为主的地方性疾病。属中医“痹症”范畴，其发生发展与瘀血密切相关。中药以其价格低廉、疗效安全，属于天然性植物药，越来越受到研究者的关注，丹参酮IIA (Tanshinone IIA, Tan IIA)是中药丹参的主要有效成分，具有抗炎、保护软骨细胞外基质(ECM)、抗血小板聚集、抗血栓形成等作用，对多种痹症有效，目前尚未有丹参酮IIA应用于大骨节病的研究，本文探讨了丹参酮IIA可能应用于大骨节病的潜在机制，以期为大骨节病的治疗提供新的思路。
Abstract: Kashin-Beck disease (KBD) is a regional disease primarily characterized by articular cartilage lesions. It falls under the category of “bi syndrome” in traditional Chinese medicine, and its development is closely related to blood stasis. Chinese herbal medicine, known for its low cost and safe efficacy, is increasingly gaining the attention of researchers as a natural plant-based remedy. Tanshinone IIA (Tan IIA), the main active ingredient in the Chinese herb Danshen, possesses anti-inflammatory properties, protects the extracellular matrix (ECM) of chondrocytes, prevents platelet aggregation, and inhibits thrombus formation, among other effects. It has been effective against various types of bi syndrome. To date, there has been no research on the application of Tanshinone IIA in the treatment of Kashin-Beck disease. This article explores the potential mechanisms by which Tanshinone IIA could be applied to Kashin-Beck disease, with the aim of providing new perspectives for its treatment.
文章引用：邢颖, 丁晓清, 阮涛, 赵云舟, 徐柯, 张杰. 丹参酮IIA治疗大骨节病的潜在机制探讨[J]. 临床个性化医学, 2024, 3(4): 1504-1509. https://doi.org/10.12677/jcpm.2024.34215

参考文献

[1] 张立毅, 林剑浩. 大骨节病的治疗方法及研究进展[J]. 中华地方病学杂志, 2021, 40(3): 248-252.
[2] 苗飞翔, 易智. 成人大骨节病的治疗进展[J]. 中华地方病学杂志, 2021, 40(6): 513-516.
[3] Zhang, Y., He, Y., Zhang, D., Zhang, M., Wang, M., Zhang, Y., et al. (2018) Death of Chondrocytes in Kashin‐beck Disease: Apoptosis, Necrosis or Necroptosis? International Journal of Experimental Pathology, 99, 312-322. [Google Scholar] [CrossRef] [PubMed]
[4] Xu, J., Wang, J. and Zhao, H. (2022) The Prevalence of Kashin-Beck Disease in China: A Systematic Review and Meta-analysis. Biological Trace Element Research, 201, 3175-3184. [Google Scholar] [CrossRef] [PubMed]
[5] 中华人民共和国国家卫生健康委员会. 2022年中国卫生健康统计年鉴[EB/OL]. 2023-05-17.
http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb.shtml, 2024-09-18.
[6] Zeng, C., Wei, J., Persson, M.S.M., Sarmanova, A., Doherty, M., Xie, D., et al. (2018) Relative Efficacy and Safety of Topical Non-Steroidal Anti-Inflammatory Drugs for Osteoarthritis: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials and Observational Studies. British Journal of Sports Medicine, 52, 642-650. [Google Scholar] [CrossRef] [PubMed]
[7] 张建业, 张卫华, 韩俊, 陈东. 丹参酮IIA抑制软骨细胞炎症、软骨基质降解的机制及对大鼠骨关节炎的影响[J]. 解放军医药杂志, 2021, 33(3): 10-16.
[8] 夏晓晓, 黄耀凯, 李中琼. 丹参酮IIA防治骨性关节炎的研究进展[J]. 现代药物与临床, 2024, 39(5): 1365-1368.
[9] 王继成, 易智. 大骨节病病因与发病机制的研究进展[J]. 中国骨与关节杂志, 2018, 7(12): 941-945.
[10] 彩云, 吴宪昊, 孙丽艳. 大骨节病关节软骨损伤发病机制研究进展[J]. 中华地方病学杂志, 2020, 39(2): 150-153.
[11] 薛森海, 王治伦, 陈静宏, 等. 低硒条件下T-2毒素对大鼠多种组织抗氧化酶的影响[J]. 中国地方病防治杂志, 2014, 29(4): 256-257.
[12] Cao, J., Li, S., Shi, Z., Yue, Y., Sun, J., Chen, J., et al. (2008) Articular Cartilage Metabolism in Patients with Kashin-Beck Disease: An Endemic Osteoarthropathy in China. Osteoarthritis and Cartilage, 16, 680-688. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, X., Ning, Y., Zhang, P., Poulet, B., Huang, R., Gong, Y., et al. (2021) Comparison of the Major Cell Populations among Osteoarthritis, Kashin-Beck Disease and Healthy Chondrocytes by Single-Cell NA-Seq Analysis. Cell Death & Disease, 12, Article No. 551. [Google Scholar] [CrossRef] [PubMed]
[14] 林佩琴, 著. 孔立, 校注. 类证治裁[M]. 北京: 中国中医药出版社, 1997.
[15] 王清任, 撰著. 石学文, 点校. 医林改错[M]. 沈阳: 辽宁科学技术出版社, 1997.
[16] 应小平, 张朝玉. 中医学“瘀血”的实质探析[J]. 现代中医药, 2015, 36(6): 75-77.
[17] (魏)吴普, 等, 述. (清)孙星衍, (清)孙冯翼, 辑. 神农本草经[M]. 北京: 科学技术文献出版社, 1996.
[18] 国家药典委员会. 中国药典[M]. 北京: 中国医药科技出版社, 2015.
[19] Guo, R., Li, L., Su, J., Li, S., Duncan, S.E., Liu, Z., et al. (2020) Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases. Drug Design, Development and Therapy, 14, 4735-4748. [Google Scholar] [CrossRef] [PubMed]
[20] 洪瑛, 晏为华, 刘修树. 丹参酮IIA下调NF-κB信号通路发挥对IL-1β所致软骨细胞损伤的保护作用[J]. 海峡药学, 2021, 33(6): 4-8.
[21] 彭秋伟. 丹参酮IIA缓解类风湿关节炎骨破坏的分子作用机制研究[D]: [博士学位论文]. 北京: 中国中医科学院, 2023.
[22] 岳虎. 丹参酮类化合物抑制NLRP3炎症小体激活及其防治炎症性疾病的作用研究[D]: [硕士学位论文]. 广州: 广州医科大学, 2021.
[23] 韩莉欣, 张荣强, 王慧敏, 杨晓莉, 熊咏民. 血清白细胞介素-1β、肿瘤坏死因子-α与大骨节病关系的Meta分析[J]. 西安交通大学学报(医学版), 2016, 37(6): 878-881, 905.
[24] Xiao, C. and Ghosh, S. (2005) NF-κB, an Evolutionarily Conserved Mediator of Immune and Inflammatory Responses. In: Gupta, S., Paul, W.E. and Steinman, R., Eds., Mechanisms of Lymphocyte Activation and Immune Regulation X, Springer, 41-45. [Google Scholar] [CrossRef] [PubMed]
[25] 王晨, 熊咏民. NF-κB信号通路在大骨节病等骨关节病中的研究进展[J]. 国外医学(医学地理分册), 2019(4): 466-469, 474.
[26] 戴娜, 王从安, 师彬. 丹参活性成分防治骨关节炎作用机制的研究进展[J]. 环球中医药, 2023, 16(10): 2147-2152.
[27] 彩云, 吴宪昊, 孙丽艳. 大骨节病关节软骨损伤发病机制研究进展[J]. 中华地方病学杂志, 2020, 39(2): 150-153.
[28] 武世勋, 吴翠艳, 郭雄. 大骨节病和骨性关节炎软骨细胞外基质的降解差异[J]. 西安交通大学学报(医学版), 2021, 42(2): 306-310, 316.
[29] Jia, P., Zhang, X., Zuo, H., Lu, X. and Li, L. (2017) Articular Cartilage Degradation Is Prevented by Tanshinone IIA through Inhibiting Apoptosis and the Expression of Inflammatory Cytokines. Molecular Medicine Reports, 16, 6285-6289. [Google Scholar] [CrossRef] [PubMed]
[30] 宋奕, 朱寅, 丁道芳. 丹参酮IIA对软骨细胞II型胶原及Wnt/β-catenin信号通路的影响[J]. 中国中医骨伤科杂志, 2018, 26(9): 1-4.
[31] 高世超, 殷海波, 刘宏潇. 骨关节炎从瘀论治思路探讨[J]. 中国中医药信息杂志, 2015(4): 98-99, 100.
[32] 谢林, 郭振球. 膝关节退行性骨关节病与血瘀证[J]. 湖南中医学院学报, 1996(3): 76-78.
[33] Maione, F., Cantone, V., Chini, M.G., De Feo, V., Mascolo, N. and Bifulco, G. (2015) Molecular Mechanism of Tanshinone IIA and Cryptotanshinone in Platelet Anti-Aggregating Effects: An Integrated Study of Pharmacology and Computational Analysis. Fitoterapia, 100, 174-178. [Google Scholar] [CrossRef] [PubMed]
[34] 张泽文, 王端旭, 林文杰, 等. 丹参酮IIA抑制血小板活化的G蛋白信号途径研究[J]. 国际检验医学杂志, 2017, 38(11): 1449-1451.
[35] 周娟, 王守涛, 何晓静, 等. 丹参酮IIA静脉乳剂对大鼠血液流变学及血栓形成的影响[J]. 沈阳药科大学学报, 2008, 25(2): 144-147.
[36] 郭冬, 刘珍, 张恩户. 丹参酮IIA、丹参素、川芎和阿魏酸抑制血小板聚集的相互作用类型及配比关系研究[J]. 陕西中医, 2007, 28(6): 743-745.
[37] Wang, M., Liu, L., Zhang, C.S., Liao, Z., Jing, X., Fishers, M., et al. (2020) Mechanism of Traditional Chinese Medicine in Treating Knee Osteoarthritis. Journal of Pain Research, 13, 1421-1429. [Google Scholar] [CrossRef] [PubMed]
[38] 王婉莹, 彩云, 孙丽艳. Wnt/β-catenin信号通路在骨关节炎和大骨节病发病中的作用及研究进展[J]. 中华地方病学杂志, 2018, 37(11): 933-933.